Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023

<p>Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic burden at lymphodepletion Longer-term data from a pooled analysis from the ALLCAR19 study and FELIX Phase Ib in r/r B-ALL showed durable remissions with obe-cel […]</p>
<p>The post <a href="https://forextv.com/top-news/autolus-therapeutics-presents-clinical-data-updates-at-the-american-society-of-hematology-ash-annual-meeting-2023/">Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>